Day: September 29, 2021

Type of dystonia characterized by involuntary spasms of the eyelid muscles can lead to substantial visual disturbance or functional blindness Ad Hoc Announcement Pursuant to Art. 53 LR Geneva, Switzerland, September 29, 2021 – Addex Therapeutics Ltd (SIX: ADXN, Nasdaq: ADXN), a clinical-stage pharmaceutical company pioneering allosteric modulation-based drug discovery and development, announced today the initiation of a Phase 2a clinical study with dipraglurant as a potential treatment for blepharospasm, a type of dystonia characterized by involuntary contractions or spasms of the eyelid muscles resulting in sustained eyelid closure, which can result in substantial visual disturbance or functional blindness. Dipraglurant selectively targets the metabotropic glutamate receptor subtype 5 (mGlu5) to downregulate neurotransmission through...

This announcement contains inside information for the purposes of Article 7 of the Market Abuse Regulation (EU) No 596/2014. Cambridge, UK and Indianapolis, US – 29 September 2021: Acacia Pharma Group plc (“Acacia Pharma” or the “Company”) (EURONEXT: ACPH), a commercial stage biopharmaceutical company focused on developing and commercializing novel products to improve the care of patients undergoing serious medical treatments such as surgery, invasive procedures, or cancer chemotherapy, announces that its Marketing Authorization Application (MAA) for BARHEMSYS® (amisulpride injection) has been submitted, validated and is now under formal review in major European markets. The review process is expected to be completed by Q3/2022. BARHEMSYS was approved in February 2020 by the Food and Drug Administration (FDA) for use in the United States...

Firm is the first to give investors access 25 crypto ETPs in Switzerland Zurich, September 28, 2021 – 21Shares AG (“21Shares”), the world’s largest issuer of cryptocurrency ETPs, today announced the listing of two additional cryptocurrency ETPs for a total of 25 listings on the leading Swiss exchange SIX. The new crypto index 21Shares Crypto Basket Equal Weight ETP (Ticker: HODLV) and 21Shares Crypto Basket 10 ETP (Ticker: HODLX). Jane Street will provide seed capital and serve as authorized participant for these two products. These ETPs emphasize 21Shares’ leadership in crypto ETP innovation and its research-driven product development approach:21Shares Crypto Basket Equal Weight ETP (HODLV) is a rules-based passive ETP based on the Vinter 21Shares “HODLV Index”. The HODLV Index tracks the top five eligible crypto assets, all weighted...

ASML provides strategy and financial update at virtual Investor Day meeting ASML increases long-term outlook VELDHOVEN, the Netherlands, September 29, 2021 – At the Investor Day meeting today, webcast live from its headquarters in Veldhoven, the Netherlands, ASML Holding N.V. (ASML) will provide an update on the company’s strategy, performance and long-term outlook. Chief Executive Officer Peter Wennink, together with Chief Technology Officer Martin van den Brink and Chief Financial Officer Roger Dassen and other senior executives, will discuss the company’s growth opportunities and developments in the market and technology. Company strategy, long-term outlook and value creationGlobal megatrends in the electronics industry, supported by a highly profitable and fiercely innovative ecosystem, are expected to continue to fuel growth...

September 29, 2021: Oslo, Norway, PGS on behalf of the PGS-TGS joint venture acquired over 10 000 sq.km of 3D GeoStreamer data offshore Newfoundland and Labrador between May and September this year. Fast-track results will be delivered in December 2021 and final imaging products will be ready Q1 2022.  The data from this year’s program expands the footprint of the PGS-TGS joint venture offshore Newfoundland and Labrador to approximately 80 000 sq. km. The focus of our 2021 acquisition was on the Cape Anguille survey in the Orphan Basin, with strategic additional acquisition on Lewis Hills and Jeanne d’Arc, Marine seismic acquisition on these project areas was carried out by the Ramform Atlas and Ramform Titan, in compliance with strict Covid-19 guidelines.  “We are very pleased the PGS-TGS joint venture has completed the 11th consecutive...

– Rapid and sustained improvement in urticaria control after single dose of CDX-0159 –– Greatly improved patient quality of life and reduced disease impact –– Data further support 95% complete response rate to provocation testing – HAMPTON, N.J., Sept. 29, 2021 (GLOBE NEWSWIRE) — Celldex Therapeutics, Inc. (NASDAQ:CLDX) today announced positive data on measurements of symptom control and quality of life from the Company’s ongoing, open label Phase 1b clinical trial of CDX-0159 in patients with antihistamine refractory cold urticaria and symptomatic dermographism, the two most common forms of chronic inducible urticaria. These diseases, which are often severe and debilitating, can significantly impact patients’ lives. CDX-0159 is a humanized monoclonal antibody that specifically binds the receptor...

HighlightsUpdated Measured and Indicated resource for the Maricunga Stage One Lithium Brine Project in Chile confirmed an increase by 90 per cent compared with 2019 Definitive Feasibility Study. Measured and Indicated (M&I) resource now estimated as 1,905,000 tonnes of Lithium Carbonate Equivalent (LCE) for the Stage One (Old Code) mining properties at an average grade of 953 mg/l lithium. This increase in M+I Resources is in addition to the M+I Resources (2018) of 184 Kt Lithium (979 Kt LCE) in the Litio 1-6 (New Code) concessions to a depth of 200 m. The Maricunga resource remains open at depth, with a new exploration target for further resource expansion between 400m-550m in the Stage One concessions. The DFS update for the Stage One continues as expected by Worley, GEA Messo and Atacama Waters. The latest drilling for the resource...